Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012492 · ClinicalTrials.gov registry record · Phase 2
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
A Phase 2 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01012492 is a Phase 2 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 11 participants.
The verdict
NCT01012492, a Phase 2 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood stem cell grafts.
Interventions
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012492
The ClinicalTrials.gov registry entry for NCT01012492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT01012492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01012492 about?
NCT01012492 is a clinical study titled "Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT". The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood stem cell grafts.
What is the current status of trial NCT01012492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2009-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01012492?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT01012492?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.